AseBio and CSIC Sign a Framework Agreement to Promote Collaboration in R&D&I

The Spanish Association of Biotechnology Companies (AseBio) and the Spanish National Research Council (CSIC) signed a framework agreement with the aim of facilitating the development of projects in the field of scientific research and innovation in biotechnology between CSIC researchers and the association’s biotechnology companies.

According to the employers’ association, the main mission is to “promote the transfer of technology and the impact on society of the excellent science and innovation carried out in Spain in the field of biotechnology.” Through this rubric, a relationship of collaboration and support between both entities that began in 2000 is continued, with Csic as one of the founding partners of AseBio.

“This new framework for collaboration represents a step forward of enormous significance, through which we will explicitly unite all the scientific and innovative power of CSIC and all the research, technical and technology evaluation experience of the other AseBio partners,” said CSIC President Eloísa del Pino at the signing ceremony of the document.

Asebio and CSIC will be deploying several initiatives in the coming months

Thus, AseBio assures that “the joint work carried out over these years has made it possible to respond to crucial moments such as the pandemic caused by Covid-19”. In this sense, they recall that in April 2020, Csic, through its Global Health Platform, together with AseBio, organized joint activities to establish contact and promote collaboration between Csic groups and AseBio partner companies in technologies related to the diagnosis of coronavirus .

In addition, they highlight the dissemination work and collaboration by AseBio in the Csic Cocrea programs and the Camino initiative (Career Mentoring Initiative for New Opportunities). The first, launched in 2023 by the Vice-Presidency of Innovation and Transfer of the Csic, was created to promote co-creation and co-development projects with companies in the face of global challenges, and AseBio contributed to boosting the participation of biotechnology companies in the call and subsequently participated in the evaluation committee.

AseBio highlights that Camino was launched in 2021 “as a meeting point between CSIC doctoral students and highly qualified professionals, to promote an inspiring and fruitful relationship that enables them to advance in their professional careers and personal growth.”

In the coming months, CSIC and AseBio will be deploying the signed agreement through initiatives, some of which are already underway, such as the RST Biomed project, which aims to act as a “one-stop shop” for companies that collaborate with CSIC in drug discovery and development , where AseBio is helping to identify the needs of Spanish biotechnology companies to ensure that RST Biomed responds to them.

“The signing of this agreement formalizes and deepens a long-established relationship between AseBio and CSIC, which has allowed us to strengthen public-private collaboration in scientific research and biotechnological innovation over the years. The transfer of technology and knowledge are key for AseBio as a basis for biotechnological innovations to be translated into solutions to real problems in society, and collaborations such as the one we are reinforcing today with CSIC are fundamental,” concludes the president of AseBio, Rocío Arroyo.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us